Business Context and Reporting Period
This Form 8-K Current Report was filed by Alphatec Holdings, Inc. on October 22, 2010, covering events occurring on September 10, 2010, and October 22, 2010. The filing addresses unregistered sales of equity securities pursuant to Item 3.02.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures. The primary financial activity reported is the issuance of common stock:
- September 10, 2010: Issuance of 465,116 shares of common stock.
- October 22, 2010: Issuance of 476,190 shares of common stock.
- Total Issued in Period: 941,306 shares.
- Par Value: $0.0001 per share.
Material Changes
The material change reported is the completion of development milestones under the "Parcell Agreement" (a License and Supply Agreement with Parcell Spine, LLC dated January 1, 2010). These milestones triggered the issuance of the shares described above to an accredited investor. The agreement relates to intellectual property involving adult osseoprogenitor stem cells.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future outlook, or specific risk factors beyond the standard disclosure of the transaction structure. The shares were issued in reliance on exemptions from registration under Section 4(2) of the Securities Act and Rule 506 of Regulation D, as a transaction not involving a public offering. The Company is not obligated to register the resale of these shares.
Investor Verification Checklist
- Verify the total number of shares outstanding post-issuance to assess dilution impact.
- Confirm the specific development milestones achieved under the Parcell Agreement regarding adult osseoprogenitor stem cells.
- Review the full text of the Parcell Agreement to understand future payment or equity obligations.
- Check subsequent filings for any registration statements regarding the resale of these shares by the accredited investor.